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Intracerebroventricular administration of the dynorphin analog, [D-Ala2,(Fs)Phe4]-dynorphint_l~-NH2 (DAFPHEDYN) in 
rats produced diuresis and profound analgesia. Both effects were antagonized by central administration of naltrexone or 
naloxone. Intravenous administration of 10, 25, and 50 mg/kg of DAFPHEDYN failed to induce diuresis. The increased 
potency of DAFPHEDYN was apparent from the failure of an equal dose of the parent compound (dynorphin 1-13) to 
produce diuresis and the failure of [D-Ala2]-dynorphin~_~:rNH2 to produce analgesia. Radioligand binding studies indicated 
the DAFPHEDYN retains the same degree of K selectivity as the parent compound (dynorphin 1-13) though a drop in 
affinity occurred. DAFPHEDYN may be of significant interest because it retains the essential pharmacology of the parent 
compound and exhibits marked in vivo potency. 
Dynorphin r Analgesia Diuresis Opiate Naloxone Receptor 
UNEXPECTEDLY,  intraventricular administration of  
dynorphin produced few notable opiate effects [14, 16, 28, 
31, 33, 35]. Such was the case for the enkephalins as well, 
probably in part because all these peptides exhibit rapid 
breakdown upon exposure to brain membranes [2, 7, 
13, 16, 19-21, 23, 24, 30, 41]. [aH]-dynorphin, injected 
intracerebrally, is converted to SH-tyrosine and des-Tyr- 
dynorphin with exceptional rapidity [41]. Therefore, most 
studies of  the behavioral effects of  intracerebral dynorphin 
may have actually been studies of  potent nonopioid metabo- 
lite(s), especially des-Tyr-dynorphin [8, 14, 16, 17, 28, 29, 33, 
35, 36]. One approach to  inhibiting the metabolism of  opioid 
peptides is the substitution of  D-alanine in position 2 [3, 4, 
27, 32, 34]. This modification, together with an (Fs)Phe 4 
substitution, gave rise to an extremely potent analog of  
enkephalin which produced long lasting analgesia after either 
intracerebroventricular or systemic administration [5]. 
In considering the problem of enhancing the potency of  
dynorphin, the issue of  r receptor binding must be ad- 
dressed. Previous work suggested that substitution of  the 
Tyr 2 residue with D-amino acids changes the pharmacologi- 
cal properties of  the resulting analog by differentially in- 
creasing/z binding compared to r or 8 [3]. On the other hand, 
D-amino acid substitution in the carboxyl region produced 
an analog with greatly enhanced K receptor selectivity and 
high affinity. This analog, [D-Prol°]-dynorphin__~ (and a 
monoiodo derivative), is very selective for K receptors [10- 
12]. However, it is probably unsuitable for in vivo use be- 
cause of  the expected rapid cleavage of  Tyr 1 discussed 
above. 
In view of  the desirability of  a stable analog of  dynorphin 
which retains the essential pharmacology of the natural pep- 
tide, we have investigated the binding and in vivo properties 
of [D-AlaZ,(Fs)Phe4]-dynorphinH3-NH2 (DAFPHEDYN). 
This compound exhibits a pattern of  selectivity for K, /z, and 
8 receptors which is very similar to that observed with 
dynorphin 1-13. DAFPHEDYN potently produces diuresis 
and profound insensitivity to thermal pain after intracere- 
broventricular microinjection. The diuretic effects are o1 
particular interest because K opiates are unique in causing 
this effect [18]. 
METHOD 
Drugs and Peptides 
DAFPHEDYN was synthesized by one of  us (D.H.C.) 
using solid phase methods generally as discussed previously 
[4]. Dynorphin, dynorphinHa, [D-Ala2]-dynorphinl_13, and 
1Requests for reprints should be addressed to J. Michael Walker, Brown University, Box 1853, Providence, RI 02912. 
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[D-AlaZ]-dynorphin~-~3-NH2 were purchased from Peninsula 
Laboratories, Belmont, CA. Naloxone HCI and naltrexone 
HCI were generously provided by DuPont, Glenholden, PA. 
Receptor Binding 
The selectivity of the various dynorphin-like peptides for 
ix, 8 and K receptors was estimated using radioligand binding 
to rat and guinea pig brain membranes. The labelling ligands 
were aH-Tyr-D-Ala-Gly-NMe-Phe-Gly-ol (DAGO) (I nM) 
for ix receptors, 3H-[D-Ser~,LeuS,Thre]-enkephalin (DSLET) 
(1 nM) for 8 receptors and SH-bremazocine (0.2 nM) in the 
presence of 100 nM DAGO and DSLET for K receptors. 
The methods for the binding experiments were described 
in previous publications [39,40)]. Briefly then, rat and guinea 
pig brains minus cerebellum were homogenized with a 
Brinkman polytron at a concentration of 50 mg tissue per ml 
of 0.05 M TRIS buffer pH 7.4. The preparation was preincu- 
bated at 37 ° for 40 minutes. It was then centrifuged at 
30,000xg for 20 minutes and resuspended in 0.05 M TRIS 
buffer containing 0.2% bovine serum albumin (BSA) (faction 
V, Sigma). After a second incubation for 40 minutes at 25 °, 
various concentrations of the unlabelled peptides were incu- 
bated with the various tritiated ligands in a final volume of 
0.5 ml at 30 mg/ml tissue concentration. Incubations were 
carried out at 4 ° for 60 minutes. Finally, bound ligands were 
separated by f'dtration over Whatman GF/B glass fiber filters 
using the 0.05 M TRIS buffer. Nonspecific binding was esti- 
mated from tubes containing 1 /xM unlabelled ligand. The 
means of the samples in this condition were subtracted from 
values collected in competition experiments with the various 
test compounds to derive an estimate of the specific binding. 
The experiment was repeated three times. 
The Kd values of the tritiated ligands were determined in 
separate experiments from the same pools of rat and guinea 
pig brain. Scatchard analyses were performed using a com- 
puter program developed by Munson and Rodbard [25]. The 
analysis was simplified by the single component linear fits 
characteristic of the labelled ligands used in the experiments. 
The IC50 and the Kd values were then used to construct Ki 
values for the individual test compounds. 
Surgical and Injection Procedures 
At least one week before testing, cannulas were im- 
planted in the left lateral ventricles of 114 Sprague-Dawley 
rats (250-375 grams) as described previously [34]. The can- 
nulas were constructed from 24 ga thinwaU steel hypodermic 
tubing which were sharpened and beveled at the tips. Under 
sodium pentobarbital anesthesia, ventricular cannulas were 
stereotaxically placed 1 mm posterior to bregma, 1.5 mm 
lateral to the midline, and 4.1 mm below the skull surface 
(lambda and bregma at same DV). Dental acrylic and stain- 
less steel screws were used to secure the cannulas. 
A microsyringe equipped with a 31 ga needle was used for 
injections. The needle extended 0.5 mm beyond the tip of the 
cannula. Injections were conducted over a period of one 
minute in a volume of 5 ixl. 
Analgesia Testing 
Analgesia was measured by the tail flick test of D'Amour 
and Smith [6]. The apparatus consisted of an adjustable heat 
source which could be directed onto the tail of the rat. Appli- 
cation of power to the heat source started a solid state timer 
which in turn was stopped by withdrawal of the tail, allowing 
the light from the heat source to activate a photocell. A 
digital readout to tenths of a second was thereby provided 
for the latency to tail-withdrawal which is the index of pain 
responsiveness. 
Before testing, the output of the heat source was adjusted 
to obtain tail-withdrawal latencies between 2.5 and 4 sec. 
Tail flick latencies were then measured every 3 min for a 
baseline period of 15 rain. Next the peptide or control solu- 
tion was microinjected in a volume of 5 ixl, and testing con- 
tinued at 3 rain intervals for a minimum of 30 minutes or until 
tail flick latencies had returned to within 30% of their 
baseline values on three consecutive trials. 
Male Sprague-Dawley rats were prepared as above and 
used to test the analgesic potency of 5 ixg (n=8), 10 ixg (n=7), 
20 fig (n=ll) ,  and 40 ixg (n=6) of DAFPHEDYN. Each 
animal received only one injection. Separate groups of 12 
animals were tested with either the immediate parent, 
[D-Ala2]-dynorphinH3-NH2 (n=6) at a dose of 40 ixg, or 
saline (n=6). 
The ability of naloxone to antagonize the analgesic effects 
of DAFPHEDYN was tested using subcutaneous and ICV 
injections of the antagonist. In order to test the effects of 
systemically administered naloxone, animals were treated 
with either 10 mg/kg naloxone HCI or an equal volume of 
saline (n= 14). Ten minutes later DAFPHEDYN (40 fig ICV) 
was injected. The effects of centrally administered naloxone 
were tested by mixing 10 ixg naloxone HCI with 40 ixg 
DAFPHEDYN and coadministering them ICV in 5 ixl (n=7). 
These animals were compared to a separate group of rats 
(n=7) treated with 40 ixg DAFPHEDYN ICV. 
Measurement of Diuresis 
For the investigation of the effects of DAFPHEDYN on 
diuresis, rats underwent surgery for placement of lateral ven- 
tricular cannulas using the procedures described above. 
After a recovery period of at least one week, the rats were 
microinjected with saline (n=4), DAFPHEDYN 0.125 ixg 
(n=5), 0.5 ixg (n=5), 2 ixg (n=7), or dynorphinH3 2 ixg (n=6) 
and placed in metabolism cages for a two hour period during 
which the urine was collected. At the end of the period urine 
volume was recorded. 
Naltrexone, rather than naloxone, was used for studies of 
opiate antagonism of the diuretic effects of DAFPHEDYN 
because it exhibits a longer duration of action. Rats were 
either injected subcutaneously (2 mg/kg) 10 minutes before 
DAFPHEDYN administration (n=8), or naltrexone (20/~g) 
was mixed with 2 fig DAFPHEDYN and microinjected 
(n=7). As above, the rats were then placed in metabolism 
cages for a period of two hours. 
Studies of the ability of DAFPHEDYN to induce diuresis 
after intravenous administration were carried out using 100 
to 120 gram male Sprague-Dawley rats. The rats were re- 
strained and DAFPHEDYN was injected into the lateral tail 
vein at 10 mg/kg (n=2), 25 mg/kg (n=2), or 50 mg/kg (n=2). 
The number of subjects was kept to a minimum because of 
the large amounts of the analog necessary for these experi- 
ments. Following injection, the rats were placed in metabo- 
lism cages for 2 hours as above, and any changes in the 
behavior of the animals were also noted. 
Histology 
After the experiments were completed, animals were 
sacrificed by an overdose of sodium pentobarbitol and in- 
jected ICV with a 2% solution of pontamine sky blue dye in 
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TABLE 1 
Dynorphin DAFPHEDYN 
Rat Guinea Pig Rat Guinea Pig 
Dynorphinl_~3 D-Ala2-dynorphinH3-NH2 





Kt values (-+SEM) of various dynorphin fragments and analogs in rat and guinea pig brain 
0.17 _+ 0.1 0.34 + 0.04 1.2 + 0.9 1.3 _ 0.8 0.15 -+ 0.1 0.05 + 0.03 1.9 _+ 0.4 1.5 + 0.03 
1.3 -+ 0.3 1.5 -- 1.1 2.0 -+ 0.1 16.4 -+ 1.7 0.4 --- 0.1 0.55 -+ 0.2 1.1 ± 0.4 1.5 -+ 0.2 




















76 O g  
• ,1E 
"ii 




- e  - e  - a  o a e o 1 2  t s  l e 2 1  2 4 2 7 a o  s 10 20 ~0 
T i m e  ( m l r l , , t e s )  OOSE (ug i¢~} 
FIG. 1. Left: Effect of various doses of DAFPHEDYN on the tail flick latency of 
rats after intracerebroventricular injection (arrow). Right: Same data plotted as 
Simpson's approximation to the integral of the change from baseline mean. 
physiological saline. Brains were fixed by the perfusion of  
10% formalin through the heart. The brain was cut with a 
scalpel and the ventricular system was checked for the pres- 
ence of  dye. 
RESULTS 
Receptor Binding 
D A F P H E D Y N  potently displaces a variety of  selective 
ligands from their binding sites in rat and guinea pig brains. 
As shown in Table 1A, the KI was found to be 1.2 nM for the 
rat brain at K receptors. Although this value reflects a ten-fold 
loss of  potency compared to dynorphinl_13, it is still well 
within the range of  potent  opiates. 
Table 1B illustrates the ratios of  the KI values at/~, x, and 
8 sites normalizing the x binding to one. Dynorphin and 
dynorphinl_13 show highest affinity for x receptors,  3 to 11- 
fold less affinity fo r / z  receptors,  and 33 to 120-fold lower 
affinity for 8 receptors in rats and guinea pigs respectively. 
Amidation and the D-AIa 2 substitution cause a marked loss 
of selectivity resulting in an analog that is almost equipotent 
at the various receptor  types. Further  substitution of 
(F5)Phe*, however,  shifts the ratios back to values closely 
resembling the profile of  dynorphin1_13. 
Analgesia 
D A F P H E D Y N  induces profound analgesia in a dose- 
dependent  manner as shown in Fig. 1. Analysis of  variance 
indicated a highly significant effect across the doses of  the 
analog, F(3,28)=6.72,p =0.0015. The dose-relatedness of  the 
effect is readily observed in Fig. 1 (right) which plots a math- 
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FIG. 2. Left: Effect of naloxone (10 tzg ICV) coadministered with DAFPHEDYN (40/zg ICV) on mean 
tail flick latency over time. Naloxone significantly reduced the analgesic efficacy of DAFPHEDYN. 
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FIG. 3. Tail flick latency before and after treatment with 
[D.Ala2]-dynorphinl_13-NH~ (ICV 40/~g). This compound, the im- 
mediate parent of DAFPHEDYN, fails to produce analgesia. © 
Saline, t [D-Ala2]-dynorphim-l.~-NH~. 
ematical approximation of  the integral of  the post injection 
tail flick latency adjusted for the baseline average. 
Naloxone, administered intracerebroventricularly, signif- 
icantly reduced the analgesic effects of  DAFPHEDYN,  This 
effect, which is illustrated in Fig. 2, was confirmed statisti- 
cally, t(6)=4.59, p<0.005. As reported by others, difficulties 
were encountered when naloxone was administered sub- 
cutaneously [15]. Naloxone (10 mg/kg, SC) failed to signifi- 
cantly antagonize the analgesic effects of  DAFPI tEDYN.  
This was suggested by analysis of  variance which revealed a 
significant effect of  DAFPHEDYN,  F(2,12)=5.69, 
p =0.0018, but no significant loss of  efficacy in the presence 
of  SC naloxone. 
As shown in Fig. 3, the immediate parent compound, 
[D-Ala2]-dynorphin,_13-NH2, failed to produce any measur- 
able analgesia in the tail flick test at the highest dose used for 
DAFPHEDYN,  t ( l l )=  1.07, nonsignificant. 
Diuresis 
DAFPHEDYN caused dose-dependent diuretic effects. 
O 
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FIG. 4. Mean urine output collected for two hours after ICV admin- 
istration of saline, various doses of DAFPHEDYN, DAFPHEDYN 
(2 /zg) with natrexone (20 /zg) (2+NAL), or dynorphinH:~ (2 /~g) 
(DYN13). 
This action, illustrated in Fig. 4, was confirmed by one way 
analysis of  variance across the various doses of  the analog, 
F(4,20)=5.22, p<0.005. The increased potency ot 
DAFPHEDYN was apparent in a comparison with dynor- 
phin 1-13. As shown in Fig. 4, DAFPHEDYN was consid- 
erably more potent than the parent compound at the same 
dose, t(11)=2.44, p=0.03. 
When administered intracerebroventricularly, naltrexone 
reduced the diuretic effect of  DAFPHEDYN. As suggested 
by the means shown in Fig. 4, this action is statistically 
significant, t(12)=2.54, p=0.026. As with the studies of 
analgesia, naltrexone failed to show statistically significant 
antagonism at 2 mg/kg SC, 10 minutes prior to injection ot 
DAFPHEDYN,  t(13)=1.53, nonsignificant. There was, 
nevertheless, a marked drop in the mean urine output under 
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these conditions (mean DAFPHEDYN alone=5.89 ml, with 
naltrexone (2 mg/kg SC)=3.25 ml). 
Intravenous administration of DAFPHEDYN failed to 
evoke significant diuresis. Although the number of subjects 
was small, the lack of effect was readily apparent from the 
means of urine output (ml): saline: 0.55; DAFPHEDYN: 10 
mg/kg: 0.0, 25 mg/kg: 0.30, 50 mg/kg: 0.69. The appearance 
of a slight effect was not statistically significant by one way 
analysis of variance across the drug doses, F(3,6)=2,41, ns. 
Likewise, the urine output after 2/zg DAFPHEDYN ICV 
was 8 times greater than after 50 mg/kg intravenously. 
Animals treated with the highest dose of DAFPHEDYN 
intravenously did exhibit marked but transient behavioral 
change. These included a profound lethargy and lack of 
movement for a period of one or two minutes immediately 
after the injection. 
DISCUSSION 
DAFPHEDYN and dynorphinl_la (the parent compound) 
exhibit similar patterns of receptor selectivity as judged by 
the Ki values obtained in competition experiments. It seems 
possible that other substitutions might well increase the r 
selectivity further. Nevertheless, results from both rat and 
guinea pig brains are strongly indicative of a r receptor pref- 
erence in DAFPHEDYN, in spite of a ten-fold drop in bind- 
ing affinity. This drop in binding affinity is apprently com- 
pensated for by increased resistance to metabolism because 
DAFPHEDYN exhibits considerable in vivo potency. 
DAFPHEDYN potently induces diuresis and analgesia 
which can be reversed by naloxone or naltrexone. The in- 
crease in potency is reminiscent of a similar increase ob- 
served with a fluorinated analog of [D-AlaZ,MetS] - 
enkephalin-NH2 [5 ] .  However, the enkephalin and 
dynorphin analogs differ in that the enkephalin analog 
produced analgesia that was very susceptible to naloxone. 
The weak actions of systemically administered naloxone 
with DAFPHEDYN are consistent with difficulties 
encountered by others when opiate agonists were adminis- 
tered ICV [15]. It has also been found that kappa opiates are 
quite resistant to naloxone [22,38] and that dynorphin may 
exhibit increased potency because it disassociates from its 
receptors very slowly [9]. Conceivably, a combination of 
these factors gave rise to the lack of significant antagonism 
by systemically administered naloxone. Nevertheless, 
naloxone and naltrexone were effective when co- 
administered with DAFPHEDYN, which strongly supports 
the notion that DAFPHEDYN acted through opiate recep- 
tors. 
The in vivo effects of DAFPHEDYN appear to be 
mediated, at least in part, through r receptors. Previous 
work has shown that/~ and K opiates exhibit different effects 
on urine output. Kappa-selective opiates have diuretic ef- 
fects, whereas/~ selective opiates generally have antidiuretic 
effects [18]. The findings that DAFPHEDYN prefers K re- 
ceptors in vitro and produces diuretic effects in vivo that are 
susceptible only to relatively high doses of naloxone or nal- 
trexone all support the conclusion that the in vivo effects of 
DAFPHEDYN involve r receptors. 
It is certainly conceivable that some effects of 
DAFPHEDYN are mediated by/~ receptors. In particular, 
the effects on tail flick after central administration are not 
expected for K agonists, although we have found moderate 
increases in tail flick latency after ICV administration of a K 
alkaloid, U50,488h (unpublished data). The /~ activity of 
DAFPHEDYN is sufficient to assume that the analgesic ef- 
fects could be # related, in spite of the only weak effects of 
systemically-administered naloxone. Since the relative af- 
finity of DAFPHEDYN for/z, K and 8 receptors so closely 
resembles that of the natural parent compound, it seems 
possible that dynorphin itself can give rise to analgesia when 
released from central neurons. Thus, although the precise 
mechanism of action of DAFPHEDYN in analgesia is pres- 
ently unknown, these analgesic effects offer some support to 
the possibility that centrally released dynorphin might cause 
thermal analgesia. 
In view of the above, it is rather surprising that the im- 
mediate parent compound [D-Ala2]-dynorphinH3-NH~ failed 
to produce analgesia after central administration. This failure 
occurred in spite of an increase in/z binding and a presumed 
higher metabolic stability. The effects of this compound are 
reminiscent of past failures of dynorphin to produce thermal 
analgesia and suggestions that dynorphin [9] or its des-Tyr 
nonopiate counterpart [36] might exhibit physiological or 
pharmacological antagonism of morphine. Viewed as a whole, 
the picture regarding central thermal analgesia with dynor- 
phin is very interesting but complex. More work is needed to 
resolve competing hypotheses which variously involve con- 
cepts of K analgesia, /.~ agonist effects of dynorphin, /x 
antagonist effects of dynorphin, or antagonism of some /~ 
effects by biologically active nonopioid dynorphin metabo- 
lites. 
Although direct evidence is lacking, it appears that 
DAFPHEDYN shows increased resistance to enzymatic deg- 
radation. In past studies of homologous opioid peptides [4, 
27, 32] including dynorphin 1-9 [26], D-Ala s substitution and 
blocking of the C-terminal by amidation were found to re- 
duce enzymatic degradation. In those cases, as in the present 
case, an increase in behavioral potency was found. In addi- 
tion, using methods previously described [41], we found that 
DAFPHEDYN is a poor inhibitor of ZH-dynorphin break- 
down (unlike many dynorphin fragments), suggesting that it 
is a poor substrate for enzyme(s) which typically cleave 
dynorphin (unpublished data). Unfortunately, these factors 
do not seem to bestow systemic potency to DAFPHEDYN 
beyond transient changes which could result from peripheral 
vascular effects. Direct studies of the breakdown of 
DAFPHEDYN are still needed to be sure that the increased 
activity in vivo is not due in part to the formation of potent 
fragments of DAFPHEDYN through enzymatic activity. 
To our knowledge DAFPHEDYN represents the first 
stable analog of dynorphin that retains a dynorphin-like bind- 
ing profile. This is of importance because although other 
stabilized analogs of dynorphin may exhibit increases in po- 
tency, they are compromised by exhibiting marked changes 
from the parent in their pharmacological profiles. Further- 
more, although there are other compounds which exhibit a 
greater degree of K selectivity, DAFPHEDYN may be of 
interest because it is closely related to dynorphin structurally 
and pharmacologically, yet its in vivo potency is markedly 
enhanced. This suggests that DAFPHEDYN could form the 
basis for future analogs of significant interest. For example, 
a combination of the present modifications with C-terminal 
substitutions such as D-Pro TM might eventually give rise to a 
stable peptide analog having great K selectivity. In addition, 
further study of fluorinated analogs of dynorphin may be of 
significance because of possible applications involving nu- 
clear magnetic resonance or positron emission tomography. 
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